Join us throughout the month for our #OctoberIs4Livers campaign, the first and only global program dedicated to public awareness, policy, and clinical practice needs to prevent and manage liver cancer while educating and empowering those living with and impacted by the disease. This month GLI collaborates with researchers, activists, health professionals, and patients to bring forth our Liver Cancer Lessons and GLI LIVE series. In an effort to increase our global impact, GLI has also partnered with clinics and hospitals around the globe to host our second Global Open House event. If you have not done so already, please visit our Liver Central website for educational material translated in new languages! Don’t forget to check out our campaign merch.
Clinical Trial Enrollment Disparities in Liver Cancer
Dr. Lionel A. Kankeu Fonkoua, a medical oncologist in the Department of Medical Oncology at Mayo Clinic, spoke about the disparities that surround liver cancer clinical trials. Dr. Fonkoua explained that, although clinical trials have strict eligibility criterias to prevent harming patients, these same criterias are creating bias by representing only the healthiest patients and tend to disproportionately exclude Black patients. Dr. Fonkoua states that if clinical trials are to be representative of the general population, then inclusion criterias must be changed.
AASLD launches new practice guidelines for prevention, diagnosis, and treatment of hepatocellular carcinoma (HCC)
The AASLD practice guidelines have been updated to reflect new clinically significant methods for prevention, diagnosis, and treatment of hepatocellular carcinoma. For instance, the recommendation for the use of ultrasound for HCC surveillance, indications for surgical therapies, and recommendations for multidisciplinary care and advanced care planning are just a few areas that have been revised in this year’s edition.
Essential Liver Patient Resource Is Updated
The National Comprehensive Cancer Network (NCCN) has released their 2023 NCCN Guidelines For Patients: Gallbladder and Bile Duct Cancers in collaboration with GLI. This year’s Guidelines For Patients covers important topics such as testing for gallbladder and bile duct cancers, gallbladder and bile duct cancer staging, and the treatment process for gallbladder and bile duct cancers.
Advances In Recurrent HCC Therapy
Although early-stage hepatocellular carcinoma (HCC) is curable, it is estimated that 50 to 70 percent of individuals experience a relapse of the illness after 5 years. The relapse individuals experience could potentially be due to inadequate resection surgery, however, it is mostly associated with the development of de novo tumors. For individuals who experience a relapse within 2 years after their surgery, their cancer is often incurable. Researchers are turning to adjuvant antiviral treatment, repeated resection, and other forms of cancer therapies as a solution. Read more.
- October 2023: GLI’s #OctoberIs4Livers Campaign
- October 27, 2023: The Turbulent Ecosystem: Climate Change’s Impact on the Latino Cancer Burden!
- October 28, 2023: Community Liver Alliance: Virtual Liver Cancer Provider Conference
- November 10 – 14, 2023: AASLD’s The Liver Meeting®Email us at firstname.lastname@example.org to set up a meeting or swing by our booth and say hello.
It’s not only important to GLI to keep you updated; we value your input and updates. This is a reminder to Liver Cancers Council members and supporters to share news to be featured in our monthly newsletter or on our Liver Central website.